On Apr. 25, 2022, Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) had approved a supplemental new drug application for Vekluryﾮ (remdesivir) for treatment of pediatric patients who are older than 28 days, weighing at least 3 kg, and are either hospitalized with COVID-19 or have mild-to-moderate COVID-19 and are considered high risk for progression to severe COVID-19, including hospitalization or death.

Under the expanded indication, a three-day Veklury treatment regimen was recommended to help prevent hospitalization in non-hospitalized COVID-19 pediatric patients who were at high risk for COVID-19 disease progression.